secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001628280-25-008650
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera FY2024 revenue $28.8M (down 24%), net loss $0.55/share; plans Phase 1 for two programs in 2025
--------------------------------------------------------------------------------

- Revenue $28.8M vs $38.0M in 2023; net loss $162.9M ($0.55 loss per share) vs $146.4M loss in 2023.
- Cash, securities and non-dilutive govt funding total approx. $840M in available liquidity.
- Cumulative partner program starts up to 96 (87 in 2023); 16 molecules in clinic (13 in 2023).
- Plans to initiate Phase 1 trials for ABCL635 and ABCL575 and start clinical manufacturing facility in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000162828025008650/0001628280-25-008650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000162828025008650/abcl-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-008650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer